Abstract:Abstract BACKGROUND AND AIMS To date, no large-scale study has evaluated the effectiveness of COVID-19 vaccines in hemodialysis patients. We sought to evaluate the effectiveness of vaccines against SARS-CoV-2 infections and death in haemodialysis patients registered in the Fresenius Medical Care (FMC) Nephrocare network. METHOD In this historical, 1:1 matched cohort study, we analysed electronic health records (EHR) of individuals receiving in-center haemodialysis therapy in FMC European dialysis clinics from 1 December 2020, to 31 May 2021 (study period). For each vaccinated patient, an unvaccinated patient was selected among patients registered in the same country and attending a dialysis session within +/–3 days from the vaccination date. Matching without replacement was based on demographics, clinical characteristics, past COVID-19 infections and a risk score representing the local (dialysis centre) background risk of infection at each vaccination date. The infection risk score was calculated from an artificial Intelligence model predicting the risk of COVID-19 outbreak in each clinic over a 2-week prediction horizon. The infection risk score was based on trends in regional COVID-19 epidemic metrics, FMC COVID-19 reporting system and clinical practice patterns. The index date was the date of the first vaccination for the vaccinated and the matching treatment date for the unvaccinated controls. To overcome violation of the proportional hazard assumption, we estimated the effectiveness of the COVID-19 vaccines in preventing infection and mortality rates as 1—hazard ratio estimated from a time-dependent extended Cox regression stratified by country and vaccine type. RESULTS We included 44 458 patients, 22 229 vaccinated and matched 22 229 unvaccinated. Distribution of covariates was balanced across study arms after matching (Figure 1A). In the effectiveness analysis on mRNA vaccines, we observed 850 SARS-CoV-2 infections and 201 COVID19-related deaths among the 28 110 patients (14 055 vaccinated and 14 055 unvaccinated) during a mean follow up time of 44 ± 40 days. In the effectiveness analysis of viral-vector vaccines, we observed 297 SARS-CoV-2 infections and 64 COVID19-related deaths among 12 888 patients (6444 vaccinated and 6444 unvaccinated) during a mean a follow-up time of 48 ± 32 days (Figure 1B). We observed 18.5/100 patient-year and 8.5/100 patient-year fewer infections and 5.4/100 patient-year and 5.2/100 patient-year fewer COVID-19-related deaths among patients vaccinated with mRNA and viral-vector vaccines respectively, as compared to matched unvaccinated controls. The effectiveness of COVID-19 vaccines concerning both symptomatic infections and COVID-related death along the follow up period is shown in Figure 2. CONCLUSION In this matched, historical cohort study, we observed a strong reduction in both SARS-CoV-2 symptomatic infection and COVID-19-related death among dialysis patients receiving an mRNA vaccine. Despite seemingly less protective against symptomatic infections, we observed similar reduction in COVID-19 mortality rate among patients receiving a viral-carrier vaccine.

Evolving impact of the COVID-19 pandemic in chronic dialysis recipients over the course of pandemic waves and COVID-19 vaccination rollout: a French national study.

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Poor Compliance Causes Acute Rejection in Kidney Transplant Recipients During COVID-19 Pandemic: 2 Cases Report

Ppa_a_337448 61..68

COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment

COVID-19 and kidney transplantation

Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19

Impact of COVID-19 Vaccination on Mortality and Clinical Outcomes in Hemodialysis Patients

Impact of the COVID-19 pandemic on patients with chronic kidney disease A narrative review

FC 028COVID-19 RELATED MORTALITY IN KIDNEY TRANSPLANT AND DIALYSIS PATIENTS: A COMPARATIVE, PROSPECTIVE REGISTRY BASED STUDY

FC087: Effectiveness of Covid-19 Vaccines in a Large European Haemodialysis Cohort

When the COVID-19 Pandemic Changed the Follow-Up Landscape of Chronic Kidney Disease: a Survey of Real-World Nephrology Practice.

COVID-19 in Kidney Transplant Recipients: What Did We Understand After Three Years Since the Pandemic Outbreak in Kidney Transplant Recipients?

COVID-19 epidemic investigation study of a follow-up cohort of patients with diabetic kidney disease

The impact of COVID‐19 on kidney transplantation and the kidney transplant recipient – One year into the pandemic

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

Impact of COVID-19 on renal replacement therapy: perspective from a Nigerian renal transplant centre

Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study

MO890: Modifiable and Non-Modifiable Factors Associated With Increased COVID-19 Related Mortality Among Dialysis Patients

Decoding renal impact: An in-depth study on kidney function in COVID-19 patients at a tertiary care facility

Outcome of COVID-19 in Egyptian living-donor kidney transplant recipients and relation to maintenance immunosuppressive drugs: a pilot study